BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793]
URL: https://www.wjgnet.com/1948-5182/full/v19/i18/2793.htm
Number Citing Articles
1
Ya Wen, Yi Xiang Zheng, De Ming Tan. A Comprehensive Long-Term Prognosis of Chronic Hepatitis C Patients With Antiviral Therapy; A Meta-Analysis of Studies From 2008 to 2014Hepatitis Monthly 2015; 15(5) doi: 10.5812/hepatmon.15(5)2015.27181
2
Adriaan J van der Meer. Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease?Expert Review of Gastroenterology & Hepatology 2015; 9(5): 559 doi: 10.1586/17474124.2015.1001366
3
Nobuhisa Akamatsu, Yasuhiko Sugawara, Norihiro Kokudo. Asunaprevir (BMS-650032) for the treatment of hepatitis C virusExpert Review of Anti-infective Therapy 2015; 13(11): 1307 doi: 10.1586/14787210.2015.1091724
4
Ivan Gentile, Alberto E. Maraolo, Massimo Niola, Vincenzo Graziano, Guglielmo Borgia, Mariano Paternoster. Limiting the access to direct-acting antivirals against HCV: an ethical dilemmaExpert Review of Gastroenterology & Hepatology 2016; 10(11): 1227 doi: 10.1080/17474124.2016.1234375
5
Christoph R Werner, Julia M Schwarz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12World Journal of Gastroenterology 2016; 22(35): 8050-8059 doi: 10.3748/wjg.v22.i35.8050
6
Martin Pehrsson, Tina Manon‐Jensen, Shu Sun, Ida F. Villesen, Helena Castañé, Jorge Joven, Keyur Patel, Zachary Goodman, Mette J. Nielsen, Anne‐Christine Bay‐Jensen, Diana J. Leeming, Joachim H. Mortensen, Morten A. Karsdal. An MMP ‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution Liver International 2022;  doi: 10.1111/liv.15270
7
Nicola Coppola, Ivan Gentile, Giuseppe Pasquale, Antonio Riccardo Buonomo, Nicolina Capoluongo, Maria D’Armiento, Guglielmo Borgia, Evangelista Sagnelli. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis CAnnals of Hepatology 2014; 13(1): 20 doi: 10.1016/S1665-2681(19)30900-7
8
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Giuseppe Castaldo, Guglielmo Borgia. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infectionExpert Opinion on Investigational Drugs 2014; 23(4): 561 doi: 10.1517/13543784.2014.892581
9
O. Tronina, K. Ślubowska, N. Mikołajczyk-Korniak, E. Komuda-Leszek, R. Wieczorek-Godlewska, B. Łągiewska, M. Pacholczyk, W. Lisik, M. Kosieradzki, M. Durlik. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature ReviewTransplantation Proceedings 2017; 49(6): 1409 doi: 10.1016/j.transproceed.2017.01.077
10
Keol Lee, Dong Hyun Sinn, Geum-Youn Gwak, Hyun Chin Cho, Sin-Ho Jung, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio IndexGut and Liver 2016; 10(5): 796 doi: 10.5009/gnl15368
11
Chiara Rosso, Gian Paolo Caviglia, Michela Ciruolo, Alessia Ciancio, Ramy Younes, Antonella Olivero, Chiara Giordanino, Giulia Troshina, Maria Lorena Abate, Mario Rizzetto, Rinaldo Pellicano, Giorgio M. Saracco, Elisabetta Bugianesi, Antonina Smedile. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective studyMinerva Medica 2019; 110(5) doi: 10.23736/S0026-4806.19.06108-1
12
Farina M Hanif, Zain Majid, Nasir Hassan Luck, Abbas Ali Tasneem, Syed Muddasir Laeeq, Muhammed Mubarak. Revolution in the diagnosis and management of hepatitis C virus infection in current eraWorld Journal of Hepatology 2022; 14(4): 647-669 doi: 10.4254/wjh.v14.i4.647
13
Christoph R Werner, Carolin Franz, Daniel P Egetemeyr, Robert Beck, Nisar P Malek, Ulrich M Lauer, Christoph P Berg. First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohortVirology Journal 2015; 12(1) doi: 10.1186/s12985-015-0261-0
14
Ho Soo Chun, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Cheol-Hyung Lee, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Seung Up Kim. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis CEuropean Journal of Gastroenterology & Hepatology 2020; 32(3): 378 doi: 10.1097/MEG.0000000000001512
15
Lingyao Du, Hong Tang. miRNA antagonism and direct-acting antivirals: could this be a novel combination treatment against HCV?Future Virology 2016; 11(12): 753 doi: 10.2217/fvl-2016-0109
16
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Nicola Coppola, Guglielmo Borgia. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infectionExpert Review of Anti-infective Therapy 2014; 12(10): 1179 doi: 10.1586/14787210.2014.945432
17
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Guglielmo Borgia. Beclabuvir for the treatment of hepatitis CExpert Opinion on Investigational Drugs 2015; 24(8): 1111 doi: 10.1517/13543784.2015.1059820
18
Maria Guarino, Anna Sessa, Valentina Cossiga, Federica Morando, Nicola Caporaso, Filomena Morisco, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadowsWorld Journal of Gastroenterology 2018; 24(24): 2582-2595 doi: 10.3748/wjg.v24.i24.2582
19
Ariel Bardach, Akram Hernández-Vásquez, Alfredo Palacios, María Calderón, Natalie Soto, Dario Balan, Federico Augustovski. Epidemiology, Use of resources, and Costs of Medical Management of Hepatitis C in Argentina, Colombia, Uruguay, and VenezuelaValue in Health Regional Issues 2019; 20: 180 doi: 10.1016/j.vhri.2019.06.004
20
Yuan-Ji Ma, Ling-Yao Du, Li-Bo Yan, Juan Liao, Xing Cheng, Wu-Wei Xie, Hong Tang. Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirinHepatobiliary & Pancreatic Diseases International 2021; 20(2): 137 doi: 10.1016/j.hbpd.2020.02.004
21
Ahmed Nagaty, Ekram W. Abd El-Wahab, Tatsuo Kanda. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in EgyptPLOS ONE 2017; 12(10): e0184654 doi: 10.1371/journal.pone.0184654
22
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Emanuela Zappulo, Giuseppe Castaldo, Guglielmo Borgia. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infectionExpert Opinion on Investigational Drugs 2014; 23(5): 719 doi: 10.1517/13543784.2014.902049
23
Antonio Craxì, Carlo Federico Perno, Mauro Viganò, Francesca Ceccherini-Silberstein, Salvatore Petta, Alessio Aghemo, Alfredo Alberti, Pietro Andreone, Massimo Andreoni, Stefano Bonora, Maurizia Rossana Brunetto, Savino Bruno, Nicola Caporaso, Antonio Chirianni, Alessia Ciancio, Elisabetta Degasperi, Giovanni Di Perri, Stefano Fagiuoli, Carlo Ferrari, Giovanni Battista Gaeta, Adriano Pellicelli, Massimo Puoti, Giovanni Raimondo, Gloria Taliani, Erica Villa, Anna Linda Zignego. From current status to optimization of HCV treatment: Recommendations from an expert panelDigestive and Liver Disease 2016; 48(9): 995 doi: 10.1016/j.dld.2016.06.004
24
Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J. Jeyarajan, Jacinta A. Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang, Wenyu Lin, Raymond T. Chung. The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysisLiver International 2021; 41(10): 2341 doi: 10.1111/liv.14976
25
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology 2015; 62(3): 932 doi: 10.1002/hep.27950
26
Sebastian Bernuth, Eray Yagmur, Detlef Schuppan, Martin F. Sprinzl, Anca Zimmermann, Arno Schad, Jens M. Kittner, Veronika Weyer, Johanna Knapstein, Jörn M. Schattenberg, Marcus A. Wörns, Peter R. Galle, Tim Zimmermann. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvirDigestive and Liver Disease 2016; 48(3): 291 doi: 10.1016/j.dld.2015.09.015
27
Horng-Maw Chen, Tsung-Hsueh Lu, Kun-Chia Chang, Kuan-Ying Lee, Ching-Ming Cheng. Opioid users with comorbid hepatitis C spent more time in agonist therapy: A 6-year observational study in TaiwanAddictive Behaviors 2017; 72: 133 doi: 10.1016/j.addbeh.2017.03.028
28
Luca Rinaldi, Maria Guarino, Alessandro Perrella, Pia Clara Pafundi, Giovanna Valente, Luca Fontanella, Riccardo Nevola, Barbara Guerrera, Natalina Iuliano, Michele Imparato, Alessio Trabucco, Ferdinando Carlo Sasso, Filomena Morisco, Antonio Ascione, Guido Piai, Luigi Elio Adinolfi. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life ExperienceDigestive Diseases and Sciences 2019; 64(10): 3013 doi: 10.1007/s10620-019-05604-8
29
Ira M. Jacobson, Joseph K. Lim, Michael W. Fried. American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C InfectionGastroenterology 2017; 152(6): 1578 doi: 10.1053/j.gastro.2017.03.018
30
Ahmed Nagaty, Sherine H A Helmy, Ekram W Abd El-Wahab. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in EgyptTransactions of The Royal Society of Tropical Medicine and Hygiene 2020; 114(3): 200 doi: 10.1093/trstmh/trz079
31
Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis CExpert Opinion on Drug Discovery 2015; 10(12): 1363 doi: 10.1517/17460441.2015.1094051
32
Longteng Ma, Jiluo Liu, Wei Wang, Fan Yang, Ping Li, Shiliang Cai, Xinyu Zhou, Xi Chen, Xun Zhuang, Hongwei Zhang, Guangwen Cao. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patientsFuture Oncology 2020; 16(11): 675 doi: 10.2217/fon-2019-0845
33
Fanpu Ji, Zhifang Cai, Hong Deng. Relapse of hepatitis C in three immunocompetent patients achieved a sustained virological response following interferon-based antiviral therapyJournal of Clinical Virology 2013; 58(3): 590 doi: 10.1016/j.jcv.2013.08.026
34
Ivan Gentile, Nicola Coppola, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virusExpert Opinion on Investigational Drugs 2014; 23(9): 1211 doi: 10.1517/13543784.2014.921680
35
Ragesh Babu Thandassery, Saad Al Kaabi, Madiha E. Soofi, Benjamin Tharian, Rajvir Singh. Noninvasive serum models to predict significant liver related events in chronic hepatitis CHepatology International 2017; 11(4): 401 doi: 10.1007/s12072-017-9800-7
36
Maissa El-Raziky, Marwa Khairy, Ahmed Fouad, Ahmed Salama, Aisha Elsharkawy, Omnia Tantawy. Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing RegimensJournal of Interferon & Cytokine Research 2018; 38(3): 129 doi: 10.1089/jir.2017.0137
37
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Guglielmo Borgia. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virusExpert Review of Anti-infective Therapy 2014; 12(7): 775 doi: 10.1586/14787210.2014.920254
38
Rahul Mahapatra, Jack Fuhrer. HIV and GI Tract ComplicationsClinical Gastroenterology 2019; : 91 doi: 10.1007/978-3-030-13377-1_5
39
M. Guarino, F. Morisco, M. R. Valvano, A. M. Ippolito, M. Librandi, N. Andriulli, M. Greco, A. Amoruso, A. Iacobellis, G. Niro, N. Caporaso, A. Andriulli. Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosisAlimentary Pharmacology & Therapeutics 2017; 45(9): 1193 doi: 10.1111/apt.14017
40
A. Olveira, L. Domínguez, J. Troya, A. Arias, F. Pulido, P. Ryan, L. M. Benítez, J. González-García, M. L. Montes. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antiviralsJournal of Viral Hepatitis 2018; 25(7): 818 doi: 10.1111/jvh.12883
41
Nicola Coppola, Stefania De Pascalis, Mariantonietta Pisaturo, Laurenza Paradiso, Margherita Macera, Nicolina Capoluongo, Loredana Alessio, Maria Stanzione, Caterina Sagnelli, Carmine Minichini, Evangelista Sagnelli. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cellsJournal of Clinical Virology 2013; 58(4): 748 doi: 10.1016/j.jcv.2013.09.014
42
Ivan Gentile, Antonio Riccardo Buonomo, Guglielmo Borgia. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infectionExpert Review of Anti-infective Therapy 2014; 12(9): 1033 doi: 10.1586/14787210.2014.940898
43
Ivan Gentile, Emanuela Zappulo, Antonio Riccardo Buonomo, Riccardo Scotto, Guglielmo Borgia. Asunaprevir for hepatitis C: a safety evaluationExpert Opinion on Drug Safety 2015; 14(10): 1631 doi: 10.1517/14740338.2015.1084287
44
Sara Cuesta-Sancho, Mercedes Márquez-Coello, Francisco Illanes-Álvarez, Denisse Márquez-Ruiz, Ana Arizcorreta, Fátima Galán-Sánchez, Natalia Montiel, Manuel Rodriguez-Iglesias, José-Antonio Girón-González. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological responseWorld Journal of Hepatology 2022; 14(1): 62-79 doi: 10.4254/wjh.v14.i1.62
45
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Discontinued drugs in 2012 – 2013: hepatitis C virus infectionExpert Opinion on Investigational Drugs 2015; 24(2): 239 doi: 10.1517/13543784.2015.982274
46
Ivan Gentile, Antonio Riccardo Buonomo, Emanuela Zappulo, Guglielmo Borgia. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Expert Review of Anti-infective Therapy 2014; 12(7): 763 doi: 10.1586/14787210.2014.929497
47
Hye Won Lee, Young Eun Chon, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kyu Sik Jung, Young Nyun Park, Kwang-Hyub Han. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological ResponseGut and Liver 2016; 10(3) doi: 10.5009/gnl15021
48
Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Ivana Filipovic, Jennifer C. Samp, Derek Misurski. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infectionJournal of Medical Economics 2016; 19(10): 983 doi: 10.1080/13696998.2016.1189920